Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Laboratorio Reig Jofre

BME:RJF
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RJF
BME
€148M
Market Cap
  1. Home
  2. ES
  3. Pharmaceuticals & Biotech
Company description

Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and nutritional supplements. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
  • Laboratorio Reig Jofre has significant price volatility in the past 3 months.
RJF Share Price and Events
7 Day Returns
1.5%
BME:RJF
10.3%
Europe Pharmaceuticals
6.6%
ES Market
1 Year Returns
-19.7%
BME:RJF
-0.6%
Europe Pharmaceuticals
-26.3%
ES Market
RJF Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Laboratorio Reig Jofre (RJF) 1.5% -13% -20.6% -19.7% -42.7% -66.9%
Europe Pharmaceuticals 10.3% -3.8% -9.3% -0.6% 5% -6%
ES Market 6.6% -21.9% -28% -26.3% -32.6% -40.2%
1 Year Return vs Industry and Market
  • RJF underperformed the Pharmaceuticals industry which returned -0.6% over the past year.
  • RJF outperformed the Market in Spain which returned -26.3% over the past year.
Price Volatility
RJF
Industry
5yr Volatility vs Market

RJF Value

 Is Laboratorio Reig Jofre undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Laboratorio Reig Jofre to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Laboratorio Reig Jofre.

BME:RJF Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.3%
Perpetual Growth Rate 10-Year ES Government Bond Rate 0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BME:RJF
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year ES Govt Bond Rate 0.4%
Equity Risk Premium S&P Global 7.5%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.691 (1 + (1- 25%) (38.72%))
0.927
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.39% + (0.927 * 7.46%)
7.31%

Discounted Cash Flow Calculation for BME:RJF using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Laboratorio Reig Jofre is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BME:RJF DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 7.31%)
2020 -2.60 Analyst x1 -2.42
2021 12.30 Analyst x1 10.68
2022 19.09 Est @ 55.24% 15.45
2023 26.50 Est @ 38.79% 19.99
2024 33.73 Est @ 27.27% 23.70
2025 40.20 Est @ 19.2% 26.33
2026 45.66 Est @ 13.56% 27.87
2027 50.04 Est @ 9.61% 28.46
2028 53.47 Est @ 6.84% 28.34
2029 56.09 Est @ 4.91% 27.71
Present value of next 10 years cash flows €206.00
BME:RJF DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €56.09 × (1 + 0.39%) ÷ (7.31% – 0.39%)
€814.00
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €814.00 ÷ (1 + 7.31%)10
€402.09
BME:RJF Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €206.00 + €402.09
€608.09
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €608.09 / 75.67
€8.04
BME:RJF Discount to Share Price
Calculation Result
Value per share (EUR) From above. €8.04
Current discount Discount to share price of €2.00
= -1 x (€2.00 - €8.04) / €8.04
75.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Laboratorio Reig Jofre is available for.
Intrinsic value
>50%
Share price is €2 vs Future cash flow value of €8.04
Current Discount Checks
For Laboratorio Reig Jofre to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Laboratorio Reig Jofre's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Laboratorio Reig Jofre's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Laboratorio Reig Jofre's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Laboratorio Reig Jofre's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BME:RJF PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €0.07
BME:RJF Share Price ** BME (2020-03-31) in EUR €2
Europe Pharmaceuticals Industry PE Ratio Median Figure of 55 Publicly-Listed Pharmaceuticals Companies 19.58x
Spain Market PE Ratio Median Figure of 147 Publicly-Listed Companies 14.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Laboratorio Reig Jofre.

BME:RJF PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BME:RJF Share Price ÷ EPS (both in EUR)

= 2 ÷ 0.07

28.85x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Laboratorio Reig Jofre is overvalued based on earnings compared to the Europe Pharmaceuticals industry average.
  • Laboratorio Reig Jofre is overvalued based on earnings compared to the Spain market.
Price based on expected Growth
Does Laboratorio Reig Jofre's expected growth come at a high price?
Raw Data
BME:RJF PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 28.85x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
25.3%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.41x
Spain Market PEG Ratio Median Figure of 79 Publicly-Listed Companies 0.98x

*Line of best fit is calculated by linear regression .

BME:RJF PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 28.85x ÷ 25.3%

1.14x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Laboratorio Reig Jofre is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Laboratorio Reig Jofre's assets?
Raw Data
BME:RJF PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €2.35
BME:RJF Share Price * BME (2020-03-31) in EUR €2
Europe Pharmaceuticals Industry PB Ratio Median Figure of 110 Publicly-Listed Pharmaceuticals Companies 2.43x
Spain Market PB Ratio Median Figure of 191 Publicly-Listed Companies 1.21x
BME:RJF PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BME:RJF Share Price ÷ Book Value per Share (both in EUR)

= 2 ÷ 2.35

0.85x

* Primary Listing of Laboratorio Reig Jofre.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Laboratorio Reig Jofre is good value based on assets compared to the Europe Pharmaceuticals industry average.
X
Value checks
We assess Laboratorio Reig Jofre's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Laboratorio Reig Jofre has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RJF Future Performance

 How is Laboratorio Reig Jofre expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Laboratorio Reig Jofre expected to grow at an attractive rate?
  • Laboratorio Reig Jofre's earnings growth is expected to exceed the low risk savings rate of 0.4%.
Growth vs Market Checks
  • Laboratorio Reig Jofre's earnings growth is expected to exceed the Spain market average.
  • Laboratorio Reig Jofre's revenue growth is expected to exceed the Spain market average.
Annual Growth Rates Comparison
Raw Data
BME:RJF Future Growth Rates Data Sources
Data Point Source Value (per year)
BME:RJF Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 25.3%
BME:RJF Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 6.4%
Europe Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 13.1%
Europe Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.7%
Spain Market Earnings Growth Rate Market Cap Weighted Average 11.1%
Spain Market Revenue Growth Rate Market Cap Weighted Average 4.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BME:RJF Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BME:RJF Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 283 26 1
2023-12-31 281 26 1
2022-12-31 273 24 1
2021-12-31 244 32 15 1
2020-12-31 230 27 11 1
2020-03-31
BME:RJF Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 206 12 5
2019-09-30 199 7
2019-06-30 188 16 9
2019-03-31 188 9
2018-12-31 185 15 9
2018-09-30 185 10
2018-06-30 179 14 9
2018-03-31 175 9
2017-12-31 172 21 9
2017-09-30 164 5
2017-06-30 164 8 7
2017-03-31 164 8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Laboratorio Reig Jofre's earnings are expected to grow significantly at over 20% yearly.
  • Laboratorio Reig Jofre's revenue is expected to grow by 6.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BME:RJF Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Laboratorio Reig Jofre Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BME:RJF Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.20 0.20 0.20 1.00
2020-12-31 0.14 0.14 0.14 1.00
2020-03-31
BME:RJF Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 0.07
2019-09-30
2019-06-30 0.14
2019-03-31
2018-12-31 0.14
2018-09-30
2018-06-30 0.14
2018-03-31
2017-12-31 0.14
2017-09-30
2017-06-30 0.11
2017-03-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Laboratorio Reig Jofre is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Laboratorio Reig Jofre's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Laboratorio Reig Jofre has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RJF Past Performance

  How has Laboratorio Reig Jofre performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Laboratorio Reig Jofre's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Laboratorio Reig Jofre's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • Laboratorio Reig Jofre's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Laboratorio Reig Jofre's 1-year earnings growth is negative, it can't be compared to the Europe Pharmaceuticals industry average.
Earnings and Revenue History
Laboratorio Reig Jofre's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Laboratorio Reig Jofre Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BME:RJF Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 205.83 4.94 67.81
2019-09-30 199.07 7.34 68.41
2019-06-30 188.35 9.36 66.74
2019-03-31 188.10 9.46 66.18
2018-12-31 185.29 9.27 64.95
2018-09-30 185.50 9.80 59.76
2018-06-30 178.67 9.05 58.80
2018-03-31 174.52 8.99 58.10
2017-12-31 171.73 8.83 57.99
2017-09-30 163.55 5.07 57.88
2017-06-30 163.65 7.13 57.17
2017-03-31 163.94 7.79 56.52
2016-12-31 161.48 7.68 55.46
2016-09-30 160.04 5.06 54.77
2016-06-30 159.16 4.88 54.32
2016-03-31 156.32 5.46 52.78 0.50
2015-12-31 156.91 8.75 52.52
2014-12-31 133.14 9.23 41.11
2014-09-30 121.70 9.49 32.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Laboratorio Reig Jofre has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Laboratorio Reig Jofre used its assets less efficiently than the Europe Pharmaceuticals industry average last year based on Return on Assets.
  • Laboratorio Reig Jofre's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Laboratorio Reig Jofre's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Laboratorio Reig Jofre has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RJF Health

 How is Laboratorio Reig Jofre's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Laboratorio Reig Jofre's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Laboratorio Reig Jofre is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Laboratorio Reig Jofre's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Laboratorio Reig Jofre's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 6.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Laboratorio Reig Jofre Company Filings, last reported 3 months ago.

BME:RJF Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 178.14 15.41 10.58
2019-09-30 175.17 15.40 9.54
2019-06-30 176.09 11.62 31.81
2019-03-31 151.78 14.52 11.08
2018-12-31 149.74 10.67 8.60
2018-09-30 145.55 15.00 14.23
2018-06-30 143.85 13.60 11.97
2018-03-31 143.51 16.01 13.97
2017-12-31 141.56 14.21 12.85
2017-09-30 135.84 15.53 14.60
2017-06-30 136.08 14.96 15.23
2017-03-31 135.51 17.84 14.85
2016-12-31 133.26 24.78 8.70
2016-09-30 130.08 15.38 6.05
2016-06-30 128.85 12.54 7.94
2016-03-31 128.54 13.79 10.09
2015-12-31 126.17 11.52 9.74
2014-12-31 118.17 16.41 12.34
2014-09-30 44.70 7.16 9.41
  • Laboratorio Reig Jofre's level of debt (8.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (13.9% vs 8.7% today).
  • Debt is well covered by operating cash flow (75.8%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 14.8x coverage).
X
Financial health checks
We assess Laboratorio Reig Jofre's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Laboratorio Reig Jofre has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RJF Dividends

 What is Laboratorio Reig Jofre's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Laboratorio Reig Jofre dividends. Estimated to be 0% next year.
If you bought €2,000 of Laboratorio Reig Jofre shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Laboratorio Reig Jofre's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Laboratorio Reig Jofre's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BME:RJF Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 39 Stocks 3.3%
Spain Market Average Dividend Yield Market Cap Weighted Average of 81 Stocks 5.9%
Spain Minimum Threshold Dividend Yield 10th Percentile 1.5%
Spain Bottom 25% Dividend Yield 25th Percentile 3%
Spain Top 25% Dividend Yield 75th Percentile 8.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BME:RJF Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Laboratorio Reig Jofre has not reported any payouts.
  • Unable to verify if Laboratorio Reig Jofre's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Laboratorio Reig Jofre's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Laboratorio Reig Jofre has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Laboratorio Reig Jofre's dividends in 3 years as they are not expected to pay a notable one for Spain.
X
Income/ dividend checks
We assess Laboratorio Reig Jofre's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Laboratorio Reig Jofre afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Laboratorio Reig Jofre has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RJF Management

 What is the CEO of Laboratorio Reig Jofre's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ignasi Biosca Reig
COMPENSATION €445,000
TENURE AS CEO 5.2 years
CEO Bio

Mr. Ignasi Biosca Reig has been Chief Executive Officer of Laboratorio Reig Jofre, S.A. since January 13, 2015. Mr. Reig served as Chief Executive Officer of Reig Jofre since 2006. He served as Consultant and Chief Executive Officer at Media Contacts. He is a Sole administrator of Laboratorio Medea SA, LABORATORIO FARMACEUTICO and LABORATORIO RAMON SALA, S.L ORRAVAN, S.L. He is an Administrator of GEADIC BIOTEC, A.I.E. and REIG JOFRE INVESTMENTS, S.L. He has been Executive Director of Laboratorio Reig Jofre, S.A. since December 31, 2014. He serves as a Director of BIOGLAN AB. He is a Telecommunications Engineer from the Polytechnic University of Catalonia. He holds Master in Programming and Networking for Telecom Paris Tech. (France). He holds MBA from the University of California, Berkeley (USA). He holds MBA from IESE Business School. labora

CEO Compensation
  • Insufficient data for Ignasi to compare compensation growth.
  • Insufficient data for Ignasi to establish whether their remuneration is reasonable compared to companies of similar size in .
Management Team

Ignasi Biosca Reig

TITLE
CEO & Executive Director
COMPENSATION
€445K
TENURE
5.2 yrs

Alejandro García Reig

TITLE
VP of Board & Finance Manager
COMPENSATION
€40K

Roser Zabala

TITLE
Chief Financial Officer

Gabriel Zapatero

TITLE
Managing Director of Operations

Estefanía Ruiz

TITLE
Group Chief Accountant & Controller

Victoria Serra

TITLE
Manager of Human Resources

Ignacio Vila Rocafort

TITLE
Chief Industrial Officer & Industrial GM

Antonio Ballesteros Gomez

TITLE
Managing Director of RJF Pharma - Spain

Marc Ramos

TITLE
Head of Tax & Financial Consolidation

Inma Santa-Pau

TITLE
Head of Media Relations
Board of Directors Tenure

Average tenure of the Laboratorio Reig Jofre board of directors in years:

5.3
Average Tenure
  • The tenure for the Laboratorio Reig Jofre board of directors is about average.
Board of Directors

Isabel Reig López

TITLE
Proprietary Chairman of the Board

Ignasi Biosca Reig

TITLE
CEO & Executive Director
COMPENSATION
€445K
TENURE
5.3 yrs

Alejandro García Reig

TITLE
VP of Board & Finance Manager
COMPENSATION
€40K
TENURE
1.2 yrs

Ramiro Martínez-Pardo del Valle

TITLE
Independent Director
COMPENSATION
€40K
TENURE
5.3 yrs

Emilio Moraleda Martinez

TITLE
Independent Director
COMPENSATION
€40K
TENURE
5.3 yrs

Anton Costas Comesaña

TITLE
Independent Director
COMPENSATION
€40K
TENURE
5.3 yrs

Maria Luisa Francoli Plaza

TITLE
Independent Director
COMPENSATION
€40K
AGE
65
TENURE
5.3 yrs

Ramon Gomis i de Barbara

TITLE
Independent Director
COMPENSATION
€36K
TENURE
5.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Laboratorio Reig Jofre's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Laboratorio Reig Jofre has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RJF News

Simply Wall St News

What Kind Of Share Price Volatility Should You Expect For Laboratorio Reig Jofre, S.A. (BME:RJF)?

Beta is worth considering, but it's also important to consider whether Laboratorio Reig Jofre is growing earnings and revenue. … Laboratorio Reig Jofre is a noticeably small company, with a market capitalisation of €181m. … What this means for you: Since Laboratorio Reig Jofre has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment.

Simply Wall St -

Will Laboratorio Reig Jofre, S.A.'s (BME:RJF) Earnings Grow In The Year Ahead?

Looking at Laboratorio Reig Jofre, S.A.'s (BME:RJF) recent earnings update on 30 June 2019, analyst forecasts seem pessimistic, with earnings expected to decline by 6.2% in the upcoming year against the past 5-year average growth rate of 4.4%. … In this article, I've outline a few earnings growth rates to give you a sense of the market sentiment for Laboratorio Reig Jofre in the longer term. … To reduce the year-on-year volatility of analyst earnings forecast, I've inserted a line of best fit through the expected earnings figures to determine the annual growth rate from the slope of the line.

Simply Wall St -

Is Laboratorio Reig Jofre, S.A.'s (BME:RJF) 5.3% ROE Worse Than Average?

The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Laboratorio Reig Jofre: 5.3% = €9.4m ÷ €176m (Based on the trailing twelve months to June 2019.) Most know that net profit is the total earnings after all expenses, but the concept of shareholders' equity is a little more complicated. … Combining Laboratorio Reig Jofre's Debt And Its 5.3% Return On Equity Laboratorio Reig Jofre has a debt to equity ratio of 0.18, which is far from excessive. … A company that can achieve a high return on equity without debt could be considered a high quality business.

Simply Wall St -

A Spotlight On Laboratorio Reig Jofre, S.A.'s (BME:RJF) Fundamentals

RJF's share price is trading at below its true value, meaning that the market sentiment for the stock is currently bearish. … According to my intrinsic value of the stock, which is driven by analyst consensus forecast of RJF's earnings, investors now have the opportunity to buy into the stock to reap capital gains. … We aim to bring you long-term focused research analysis driven by fundamental data.

Simply Wall St -

Read This Before Judging Laboratorio Reig Jofre, S.A.'s (BME:RJF) ROE

By way of learning-by-doing, we'll look at ROE to gain a better understanding of Laboratorio Reig Jofre, S.A. … Our data shows Laboratorio Reig Jofre has a return on equity of 6.2% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Does Laboratorio Reig Jofre, S.A. (BME:RJF) Have A Volatile Share Price?

(BME:RJF), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Introducing Laboratorio Reig Jofre, The Stock That Dropped 26% In The Last Three Years

(BME:RJF) shareholders, since the share price is down 26% in the last three years, falling well short of the market return of around 18%. … One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. … During the unfortunate three years of share price decline, Laboratorio Reig Jofre actually saw its earnings per share (EPS) improve by 0.3% per year.

Simply Wall St -

Does Laboratorio Reig Jofre, S.A. (BME:RJF) Have A Good P/E Ratio?

The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). … Laboratorio Reig Jofre has a P/E ratio of 17.73, based on the last twelve months. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

A Look At Laboratorio Reig Jofre, S.A.'s (BME:RJF) Exceptional Fundamentals

Laboratorio Reig Jofre, S.A. … is a company that has been able to sustain great financial health, trading at an attractive share price. … report on Laboratorio Reig Jofre here

Simply Wall St -

Is Laboratorio Reig Jofre SA's (BME:RJF) P/E Ratio Really That Good?

We'll look at Laboratorio Reig Jofre SA's (BME:RJF) P/E ratio and reflect on what it tells us about the company's share price. … Laboratorio Reig Jofre has a P/E ratio of 16.53, based on the last twelve months. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

RJF Company Info

Description

Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and nutritional supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include technological-specialization products, such as antibiotics, and injectable and other products; therapeutic-specialization products in the areas of dermatology, respiratory/ENT, gynecology, and pediatrics; and food supplements under the Forté Pharma brand. The company also offers research, development, and manufacturing services for pharmaceutical and biotechnology companies, and pharmaceutical manufacturers and distributors, as well as regulatory services; and licenses dossiers. It sells its products directly in 7 countries and through commercial partners in approximately 65 countries on 5 continents. Laboratorio Reig Jofre, S.A. was founded in 1929 and is based in Barcelona, Spain.

Details
Name: Laboratorio Reig Jofre, S.A.
RJF
Exchange: BME
Founded: 1929
€147,560,747
75,672,178
Website: http://www.reigjofre.com
Address: Laboratorio Reig Jofre, S.A.
Av. de les Flors,
Sant Joan Despí,
Barcelona,
Catalonia, 08970,
Spain
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BME RJF Common Shares Bolsas y Mercados Espanoles ES EUR 02. Jan 2015
DB FEQ1 Common Shares Deutsche Boerse AG DE EUR 02. Jan 2015
LSE 0RB1 Common Shares London Stock Exchange GB EUR 02. Jan 2015
BATS-CHIXE RJFE Common Shares BATS 'Chi-X Europe' GB EUR 02. Jan 2015
BME RJF EUR2 Bolsas y Mercados Espanoles ES EUR 31. Mar 2020
Number of employees
Current staff
Staff numbers
1,129
Laboratorio Reig Jofre employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 20:55
End of day share price update: 2020/03/31 00:00
Last estimates confirmation: 2020/03/02
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.